The CELLSEARCH® CTC Test is a simple, actionable blood test that helps clinicians assess the prognosis of patients with metastatic breast, prostate, or colorectal cancer.

Performed exclusively by SAM Clinical Laboratory in South East Asia, it is the only FDA approved test for enumerating CTCs. This propriety technology enriches and counts the number of CTCs in whole blood to enable the analysis of CTCs in a reproducible and reliable manner.

This count is compared against a clinically validated threshold of 3 CTCs per 7.5 ml of blood to help the clinician to know the favorability of the prognosis of the patient at anytime and get an early assessment of patient prognosis.

In the pivotal study and systematic review, the measure of CTCs was shown to provide a better prognostication of the Overall Survival (OS).

“Unfavourable compared with favourable baseline CTCs had shorter median overall survival (OS; 9.4 vs 18.5 months; P < .0001).

A reduction of CTCs below 3 after initiation of therapy predicts the OS length after initiation of therapy.”
Specimen Format Requirements

**Specimen Format**

Allow 7-day washout period for Doxorubicin before specimen collection.

1 x 10.0ml peripheral whole blood drawn into CellSave® tube*.

*CellSave® tube stabilizes circulating tumor cells (CTCs) for up to 96 hours at room temperature, which allows shipment of specimen from remote locations for analysis. CTCs are fragile and tend to degrade within a few hours when collected in standard evacuated blood collection tubes.

References


Service Workflow

- Obtain specimen collection kits from SAM LAB (via courier).
- Collect specimen as per requirement.
- Prepare specimen as per shipping instructions.
- Inform SAM LAB once specimen has been collected and picked up by courier.
- Provide shipment tracking number to facilitate specimen tracking.
- Results will be sent to you via email and mail within 2 to 5 business days.

“The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer. CTCs provide prognostic information in addition to that of imaging studies.”

More Insights Into Disease

“Changes in CTCs are significant predictors of changes in prognosis.”

**mCRC**

- No CTCs at all times (n=40)
- ≤ 4 CTCs at early disease (n=49)
- ≤ 4 CTCs at late disease (n=50)
- > 4 CTCs at healthy (n=40)
- > 4 CTCs at early disease (n=38)
- > 4 CTCs at late disease (n=39)

Median OS (Non-parametric)

P<0.0078 for all comparisons
CELLSEARCH® Circulating Tumor Cells (CTC) test for Breast Cancer

The CELLSEARCH® CTC Test is a simple, actionable blood test that helps clinicians assess the prognosis of patients with metastatic breast, prostate, or colorectal cancer.

Performed exclusively by SAM Clinical Laboratory in South East Asia, it is the only FDA approved test for enumerating CTCs. This proprietary technology enriches and counts the number of CTCs in whole blood to enable the analysis of CTCs in a reproducible and reliable manner.

This count is compared against a clinically validated threshold of 5 CTCs per 7.5 ml of blood to help the clinician to know the favorability of the prognosis of the patient at anytime and get an early assessment of patient prognosis.

In the pivotal study and systematic review, the measure of CTCs was shown to provide a better prognostication of the Overall Survival (OS).

"Median OS for patients with ≥5 CTCs, at all 5 time points were significantly shorter. OS at baseline and up to 9 to 14 weeks after the initiation of therapy were statistically significantly different."
More Accurate when CTC and Imaging are Discordant

<table>
<thead>
<tr>
<th>IMAGING</th>
<th>CTCs</th>
<th>MEDIAN OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td>Favorable</td>
<td>23.6 months [not specified]</td>
</tr>
<tr>
<td>Favorable</td>
<td>Unfavorable</td>
<td>9.2 months [not specified]</td>
</tr>
<tr>
<td>Unfavorable</td>
<td>Unfavorable</td>
<td>6.4 months [not specified]</td>
</tr>
<tr>
<td>Unfavorable</td>
<td>Favorable</td>
<td>19.9 months [not specified]</td>
</tr>
</tbody>
</table>

With discordance, CELLSEARCH® CTC Test more accurately predicts prognosis

“...the most accurate assessment of prognosis in cases where CTC and imaging are discordant in patients with metastatic breast cancer. CTCs provide prognostic information in addition to that of imaging studies." 

References

Specimen Guidelines

<table>
<thead>
<tr>
<th>Specimen Format</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen Format (CellSave® tube)</td>
<td>Allow 7-day washout period for Doxorubicin before specimen collection.</td>
</tr>
<tr>
<td></td>
<td>1 x 10.0ml peripheral whole blood drawn into CellSave® tube.</td>
</tr>
</tbody>
</table>

*CellSave® tube stabilizes circulating tumor cells (CTCs) for up to 96 hours at room temperature, which allows shipment of specimen from remote locations for analysis. CTCs are fragile and tend to degrade within a few hours when collected in standard evacuated blood collection tubes.

Service Workflow

1. Obtain specimen collection kits from SAM LAB (via courier).
2. Collect specimen as per requirement.
3. Prepare specimen as per shipping instructions. Complete test requisition forms.
4. Inform SAM LAB once specimen has been collected and picked up by courier.
5. Provide shipment tracking number to facilitate specimen tracking.
6. Results will be sent to you via email and mail within 2 to 5 business days.
The CELLSEARCH® CTC Test is a simple, actionable blood test that helps clinicians assess the prognosis of patients with metastatic breast, prostate, or colorectal cancer.

Performed exclusively by SAM Clinical Laboratory in South East Asia, it is the only FDA approved test for enumerating CTCs. This propriety technology enriches and counts the number of CTCs in whole blood to enable the analysis of CTCs in a reproducible and reliable manner.

This count is compared against a clinically validated threshold of 5 CTCs per 7.5 ml of blood to help the clinician to know the favorability of the prognosis of the patient at anytime and get an early assessment of patient prognosis.

In the pivotal study and systematic review, the measure of CTCs was shown to provide a better prognostication of the Overall Survival (OS).

“CTCs are the most accurate and independent predictor of OS in Castration Resistant Prostate Cancer.

Patients with unfavourable pretreatment CTCs had a short median OS at 2 to 20 weeks”
More Accurate when CTC and PSA are Discordant

<table>
<thead>
<tr>
<th>PSA</th>
<th>CTCs</th>
<th>MEDIAN OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td>Favorable</td>
<td>17.5 months (n=10)</td>
</tr>
<tr>
<td>Favorable</td>
<td>&lt;50% reduction</td>
<td>10.7 months (n=11)</td>
</tr>
<tr>
<td>Unfavorable</td>
<td>Unfavorable</td>
<td>8.8 months (n=7)</td>
</tr>
<tr>
<td>Unfavorable</td>
<td>Favorable</td>
<td>&gt;20.6 months (n=5)</td>
</tr>
</tbody>
</table>

"CTC counts predicted OS better than PSA decrement algorithms at all time points!"

References

Specimen Guidelines

**Specimen Format**

<table>
<thead>
<tr>
<th>Specimen Format (CellSave® tube)</th>
<th>Allow 7-day washout period for Doxorubicin before specimen collection.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 x 10.0ml peripheral whole blood drawn into CellSave® tube*.</td>
<td></td>
</tr>
</tbody>
</table>

*CellSave® tube stabilizes circulating tumor cells (CTCs) for up to 96 hours at room temperature, which allows shipment of specimen from remote locations for analysis. CTCs are fragile and tend to degrade within a few hours when collected in standard evacuated blood collection tubes.

Service Workflow

- Obtain specimen collection kits from SAM LAB (via courier).
- Collect specimen as per requirement.
- Prepare specimen as per shipping instructions. Complete test requisition forms.
- Inform SAM LAB once specimen has been collected and picked up by courier.
- Provide shipment tracking number to facilitate specimen tracking.
- Results will be sent to you via email and mail within 2 to 5 business days.